Skip to main content
. Author manuscript; available in PMC: 2008 Apr 1.
Published in final edited form as: J Neuroimmunol. 2007 Feb 27;185(1-2):168–174. doi: 10.1016/j.jneuroim.2007.01.011

Figure 1.

Figure 1

Serum levels of interleukin-10 were lower in non-responders (as defined by cumulative unique MRI lesions) over the course of 24 weeks of IFN-β therapy compared to non-responders. Standard error bars are shown.